The following six breakout discussions will be held in the exhibit hall at Cambridge Healthtech Institute’s Digital Pathology conference in San Francisco on February 13. This conference is part of the 20th Annual Molecular Med-Tri Con where more than 3,000 delegates participate in interactive lectures, discussions, and networking receptions. The Tri-Conference includes 5 concurrent symposia, the Emerging Molecular Diagnostics Partnering Forum, 18 afternoon & dinner short courses and 15 core conference programs.
Moderator: Eric F. Glassy, M.D., Medical Director, Pathology, Inc.
- What are the key drivers of epathology adoption?
- What are the main barriers to epathology adoption?
- Regulatory issues and validation issues
- What are the game-changing apps for epathology?
- What are the success stories of early adopters?
Involving Academic Pathologists and Clinical Labs while Developing Companion Diagnostics for Industry
Moderator: Steven Potts, Ph.D., CEO, Flagship Biosciences
Integrating Pathology Images and Information Systems
Moderator: Liron Pantanowitz, M.D., Associate Professor of Pathology, University of Pittsburgh Medical Center; Department of Pathology, UPMC Shadyside
- Why is there a need for the LIS to become a PACS?
- Is it better to use an LIS integrated or separate image management system?
- What will it take for digital images to drive the workflow?
- Should we share our pathology images with clinicians in the EMR?
A Systems Approach to Pathology
Moderator: Sylvia L. Asa, M.D., Ph.D., Medical Director, Laboratory Medicine Program, University Health Network and Lakeridge Health; Senior Scientist, Ontario Cancer Institute; Professor, Department of Laboratory Medicine & Pathobiology, University of Toronto
Multiplexed Imaging, Pathology and Personalized Medicine
Moderator: Richard Levenson, M.D., Professor and Vice Chair for Strategic Technologies, Department of Pathology & Laboratory Medicine, University of California Davis Medical Center
- Implications of tumor heterogeneity for multiplexed marker detection strategies–what to do with the answers?
- How do metabolomic and tumor immunotherapy approaches affect choice of markers to image?
- And what about the stroma?
Next Generation Approaches to Cellular Analysis
Moderator: Kenneth J. Bloom, M.D., Chief Medical Officer, Clarient, Inc.
> Register by January 11 and Save Up to $200!